G
Gabor Horvath
Researcher at University of Bonn
Publications - 76
Citations - 8352
Gabor Horvath is an academic researcher from University of Bonn. The author has contributed to research in topics: Inflammasome & Airway. The author has an hindex of 26, co-authored 75 publications receiving 7003 citations. Previous affiliations of Gabor Horvath include University of Miami & University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression.
Franz Bauernfeind,Gabor Horvath,Andrea Stutz,Emad S. Alnemri,Kelly S. MacDonald,David P. Speert,Teresa Fernandes-Alnemri,Jianghong Wu,Brian G. Monks,Katherine A. Fitzgerald,Veit Hornung,Eicke Latz +11 more
TL;DR: It is shown that cell priming through multiple signaling receptors induces NLRP3 expression, which is identified to be a critical checkpoint for NLRP2 activation and signals provided by NF-κB activators are necessary but not sufficient forNLRP3 activation.
Journal ArticleDOI
AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC
Veit Hornung,Veit Hornung,Andrea Ablasser,Andrea Ablasser,Marie Charrel-Dennis,Franz Bauernfeind,Franz Bauernfeind,Gabor Horvath,Daniel R. Caffrey,Eicke Latz,Katherine A. Fitzgerald +10 more
TL;DR: Using mouse and human cells, the PYHIN (pyrin and HIN domain-containing protein) family member absent in melanoma 2 (AIM2) is identified as a receptor for cytosolic DNA, which regulates caspase-1.
Journal ArticleDOI
Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP
Andrea Ablasser,Jonathan L. Schmid-Burgk,Inga Hemmerling,Gabor Horvath,Tobias Schmidt,Eicke Latz,Eicke Latz,Veit Hornung +7 more
TL;DR: Observations identify cGAS-triggered cGAMP(2′-5′) transfer as a novel host strategy that serves to rapidly convey antiviral immunity in a transcription-independent, horizontal manner.
Journal ArticleDOI
Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor.
Tengchuan Jin,Andrew J. Perry,Jiansheng Jiang,Patrick F. Smith,James A. Curry,Leonie Unterholzner,Zhaozhao Jiang,Gabor Horvath,Vijay A. K. Rathinam,Ricky W. Johnstone,Ricky W. Johnstone,Veit Hornung,Eicke Latz,Eicke Latz,Andrew G. Bowie,Katherine A. Fitzgerald,T. Sam Xiao +16 more
TL;DR: These findings provide mechanistic insights into dsDNA as the activation trigger and oligomerization platform for the assembly of large innate signaling complexes such as the inflammasomes.
Journal ArticleDOI
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
A. Sibley,Kwang Hyub Han,A. Abourached,Laurentius A. Lesmana,Mihály Makara,Wasim Jafri,Riina Salupere,Abdullah M. Assiri,Adrian Goldis,Faisal Abaalkhail,Zaigham Abbas,A. Abdou,F. Al Braiki,F. Al Hosani,K. Al Jaberi,M. Al Khatry,M. A. Al Mulla,H. Al Quraishi,A. Al Rifai,Y. Al Serkal,Altaf Alam,Seyed Moayed Alavian,Hamad I. Al-Ashgar,S. Alawadhi,L. Al-Dabal,P. Aldins,Faleh Z. Al-Faleh,Abdullah S. Alghamdi,R. Al-Hakeem,Abdulrahman Aljumah,A. Almessabi,Adel Alqutub,Khalid Alswat,Ibrahim Altraif,M. Alzaabi,N. Andrea,Mohamed A. Babatin,A. Baqir,M. T. Barakat,Ottar M. Bergmann,Abdul Rahman Bizri,Sarah Blach,Asad Chaudhry,M. S. Choi,T. Diab,Samsuridjal Djauzi,E. S. El Hassan,S. El Khoury,Chris Estes,S. Fakhry,J. I. Farooqi,J. I. Farooqi,H. Fridjonsdottir,Rino Alvani Gani,A. Ghafoor Khan,Liana Gheorghe,Magnus Gottfredsson,S. Gregorcic,Jessie Gunter,Behzad Hajarizadeh,Behzad Hajarizadeh,Saeed Hamid,Irsan Hasan,Almoutaz Hashim,Gabor Horvath,Béla Hunyady,R. Husni,Agita Jeruma,Jon G. Jonasson,Jon G. Jonasson,B. Karlsdottir,Do Young Kim,Young Seok Kim,Z. Koutoubi,Valentina Liakina,Valentina Liakina,Young-Suk Lim,A. Löve,A. Löve,Matti Maimets,Reza Malekzadeh,Mojca Maticic,Muhammad S. Memon,Shahin Merat,Jacques E Mokhbat,Fadi H. Mourad,David H. Muljono,David H. Muljono,Arif Nawaz,N. Nugrahini,S. Olafsson,S. Priohutomo,H. Qureshi,P. Rassam,Homie Razavi,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Baiba Rozentale,M. Sadik,K. Saeed,A. Salamat,Faisal M. Sanai,A. Sanityoso Sulaiman,R. A. Sayegh,Ala I. Sharara,M. Siddiq,A. M. Siddiqui,G. Sigmundsdottir,B. Sigurdardottir,Danute Speiciene,Andri Sanityoso Sulaiman,Marwa Sultan,M. Taha,Junko Tanaka,H. Tarifi,G. Tayyab,Ieva Tolmane,M. Ud Din,M. Umar,M. Umar,M. Umar,Jonas Valantinas,J. Videčnik-Zorman,Cesar Yaghi,Evy Yunihastuti,M. A. Yusuf,Bader Faiyaz Zuberi,Jonathan Schmelzer +127 more
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.